Skip Navigation


JAC Advance Access originally published online on March 19, 2008
Journal of Antimicrobial Chemotherapy 2008 61(6):1390-1392; doi:10.1093/jac/dkn118
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/6/1390    most recent
dkn118v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dégrange, S.
Right arrow Articles by Bébéar, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dégrange, S.
Right arrow Articles by Bébéar, C. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Reduced susceptibility to tetracyclines is associated in vitro with the presence of 16S rRNA mutations in Mycoplasma hominis and Mycoplasma pneumoniae

S. Dégrange, H. Renaudin, A. Charron, S. Pereyre, C. Bébéar and C. M. Bébéar*

Laboratoire de Bactériologie EA 3671, Université Victor Segalen Bordeaux 2 and CHU de Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France

* Correspondence address. Laboratoire de Bactériologie EA 3671, Mycoplasma and Chlamydiae Infections in Humans, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France. Tel: +33-5-57-57-16-25; Fax: +33-5-56-93-29-40; E-mail: cecile.bebear@u-bordeaux2.fr

Keywords: human mycoplasmas , ribosomal mutations , tetracycline resistance

The first 10% of the full text of this article appears below.

Sir,

Mycoplasma pneumoniae and Mycoplasma hominis are aetiological agents of respiratory and genitourinary tract infections, respectively, for which tetracyclines present potential for empirical treatment.1 As mycoplasmas possess a small number of rrn operons, one for M. pneumoniae and two for M. hominis, the target-related mechanism of resistance to tetracyclines caused by 16S rRNA mutations could be expected as previously described for Helicobacter pylori.2 The purpose of this study was to identify such a mechanism in the reference strains M. hominis . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?